Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma

Ildikó Krencz, Anna Sebestyén, Katalin Fábián, Ágnes Márk, Judit Moldvay, Andras Khoor, László Kopper, Judit Pápay

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Brain metastases (BMs) are common complications of adenocarcinomas (ADCs) of the lung and are associated with a poor prognosis. Although an increasing amount of data indicates that dysregulated activity of mammalian target of rapamycin (mTOR) can influence the metastatic potential of various tumors, the role of mTOR complexes in the development of BMs from ADCs of the lung is largely unknown. To estimate mTOR activity, we studied the expression of mTOR-related proteins (mTORC1: p-mTOR, p-S6; mTORC2: p-mTOR, Rictor) in primary (n = 67) and brain metastatic (n = 67) lung ADCs, including 15 paired tissue samples, using immunohistochemistry and tissue microarrays. Correlation with clinicopathological parameters was also analyzed. Increased p-mTOR, p-S6, and Rictor expressions were observed in 34%, 33%, and 37% of primary ADCs and in 79%, 70%, and 66% of BMs, respectively. Expression of these markers was significantly higher in BMs as compared with primary carcinomas (P < .0001, P < .0001, P < .001). Rictor expression was significantly higher in primary ADCs of the paired cases with BMs as compared with primary ADCs without BMs (67% versus 28%; P < .01). No other statistically significant correlations were found between mTOR activity and clinicopathological parameters. The increased mTORC1/C2 activity in a subset of pulmonary ADCs and the higher incidence of increased mTORC1/C2 activity in BMs suggest that the immunohistochemistry panel for characterizing mTOR activity and its potential predictive and prognostic role warrants further investigations.

Original languageEnglish (US)
Pages (from-to)66-73
Number of pages8
JournalHuman Pathology
Volume62
DOIs
StatePublished - Apr 1 2017

Fingerprint

Sirolimus
Neoplasm Metastasis
Brain
Proteins
S 6
Adenocarcinoma
Immunohistochemistry
TOR Serine-Threonine Kinases
mechanistic target of rapamycin complex 1
Adenocarcinoma of lung
Carcinoma
Incidence

Keywords

  • Brain metastasis
  • Immunohistochemistry
  • Lung adenocarcinoma
  • mTORC1
  • mTORC2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. / Krencz, Ildikó; Sebestyén, Anna; Fábián, Katalin; Márk, Ágnes; Moldvay, Judit; Khoor, Andras; Kopper, László; Pápay, Judit.

In: Human Pathology, Vol. 62, 01.04.2017, p. 66-73.

Research output: Contribution to journalArticle

Krencz, I, Sebestyén, A, Fábián, K, Márk, Á, Moldvay, J, Khoor, A, Kopper, L & Pápay, J 2017, 'Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma', Human Pathology, vol. 62, pp. 66-73. https://doi.org/10.1016/j.humpath.2016.12.012
Krencz, Ildikó ; Sebestyén, Anna ; Fábián, Katalin ; Márk, Ágnes ; Moldvay, Judit ; Khoor, Andras ; Kopper, László ; Pápay, Judit. / Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. In: Human Pathology. 2017 ; Vol. 62. pp. 66-73.
@article{f18201f4a40440cd85aef367903d2095,
title = "Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma",
abstract = "Brain metastases (BMs) are common complications of adenocarcinomas (ADCs) of the lung and are associated with a poor prognosis. Although an increasing amount of data indicates that dysregulated activity of mammalian target of rapamycin (mTOR) can influence the metastatic potential of various tumors, the role of mTOR complexes in the development of BMs from ADCs of the lung is largely unknown. To estimate mTOR activity, we studied the expression of mTOR-related proteins (mTORC1: p-mTOR, p-S6; mTORC2: p-mTOR, Rictor) in primary (n = 67) and brain metastatic (n = 67) lung ADCs, including 15 paired tissue samples, using immunohistochemistry and tissue microarrays. Correlation with clinicopathological parameters was also analyzed. Increased p-mTOR, p-S6, and Rictor expressions were observed in 34{\%}, 33{\%}, and 37{\%} of primary ADCs and in 79{\%}, 70{\%}, and 66{\%} of BMs, respectively. Expression of these markers was significantly higher in BMs as compared with primary carcinomas (P < .0001, P < .0001, P < .001). Rictor expression was significantly higher in primary ADCs of the paired cases with BMs as compared with primary ADCs without BMs (67{\%} versus 28{\%}; P < .01). No other statistically significant correlations were found between mTOR activity and clinicopathological parameters. The increased mTORC1/C2 activity in a subset of pulmonary ADCs and the higher incidence of increased mTORC1/C2 activity in BMs suggest that the immunohistochemistry panel for characterizing mTOR activity and its potential predictive and prognostic role warrants further investigations.",
keywords = "Brain metastasis, Immunohistochemistry, Lung adenocarcinoma, mTORC1, mTORC2",
author = "Ildik{\'o} Krencz and Anna Sebesty{\'e}n and Katalin F{\'a}bi{\'a}n and {\'A}gnes M{\'a}rk and Judit Moldvay and Andras Khoor and L{\'a}szl{\'o} Kopper and Judit P{\'a}pay",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.humpath.2016.12.012",
language = "English (US)",
volume = "62",
pages = "66--73",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma

AU - Krencz, Ildikó

AU - Sebestyén, Anna

AU - Fábián, Katalin

AU - Márk, Ágnes

AU - Moldvay, Judit

AU - Khoor, Andras

AU - Kopper, László

AU - Pápay, Judit

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Brain metastases (BMs) are common complications of adenocarcinomas (ADCs) of the lung and are associated with a poor prognosis. Although an increasing amount of data indicates that dysregulated activity of mammalian target of rapamycin (mTOR) can influence the metastatic potential of various tumors, the role of mTOR complexes in the development of BMs from ADCs of the lung is largely unknown. To estimate mTOR activity, we studied the expression of mTOR-related proteins (mTORC1: p-mTOR, p-S6; mTORC2: p-mTOR, Rictor) in primary (n = 67) and brain metastatic (n = 67) lung ADCs, including 15 paired tissue samples, using immunohistochemistry and tissue microarrays. Correlation with clinicopathological parameters was also analyzed. Increased p-mTOR, p-S6, and Rictor expressions were observed in 34%, 33%, and 37% of primary ADCs and in 79%, 70%, and 66% of BMs, respectively. Expression of these markers was significantly higher in BMs as compared with primary carcinomas (P < .0001, P < .0001, P < .001). Rictor expression was significantly higher in primary ADCs of the paired cases with BMs as compared with primary ADCs without BMs (67% versus 28%; P < .01). No other statistically significant correlations were found between mTOR activity and clinicopathological parameters. The increased mTORC1/C2 activity in a subset of pulmonary ADCs and the higher incidence of increased mTORC1/C2 activity in BMs suggest that the immunohistochemistry panel for characterizing mTOR activity and its potential predictive and prognostic role warrants further investigations.

AB - Brain metastases (BMs) are common complications of adenocarcinomas (ADCs) of the lung and are associated with a poor prognosis. Although an increasing amount of data indicates that dysregulated activity of mammalian target of rapamycin (mTOR) can influence the metastatic potential of various tumors, the role of mTOR complexes in the development of BMs from ADCs of the lung is largely unknown. To estimate mTOR activity, we studied the expression of mTOR-related proteins (mTORC1: p-mTOR, p-S6; mTORC2: p-mTOR, Rictor) in primary (n = 67) and brain metastatic (n = 67) lung ADCs, including 15 paired tissue samples, using immunohistochemistry and tissue microarrays. Correlation with clinicopathological parameters was also analyzed. Increased p-mTOR, p-S6, and Rictor expressions were observed in 34%, 33%, and 37% of primary ADCs and in 79%, 70%, and 66% of BMs, respectively. Expression of these markers was significantly higher in BMs as compared with primary carcinomas (P < .0001, P < .0001, P < .001). Rictor expression was significantly higher in primary ADCs of the paired cases with BMs as compared with primary ADCs without BMs (67% versus 28%; P < .01). No other statistically significant correlations were found between mTOR activity and clinicopathological parameters. The increased mTORC1/C2 activity in a subset of pulmonary ADCs and the higher incidence of increased mTORC1/C2 activity in BMs suggest that the immunohistochemistry panel for characterizing mTOR activity and its potential predictive and prognostic role warrants further investigations.

KW - Brain metastasis

KW - Immunohistochemistry

KW - Lung adenocarcinoma

KW - mTORC1

KW - mTORC2

UR - http://www.scopus.com/inward/record.url?scp=85014354316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014354316&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.12.012

DO - 10.1016/j.humpath.2016.12.012

M3 - Article

C2 - 28025080

AN - SCOPUS:85014354316

VL - 62

SP - 66

EP - 73

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -